Healthcare
(ABMD) Abiomed Releases Encouraging Preliminary Fourth Quarter Data
Leading cardiac assist devices maker, Abiomed Inc. (ABMD), provided encouraging preliminary data for its fourth-quarter 2013 results. The company will report full results on May 2, 2013. Revenues climbed 17% year over year...3May2013 | vitalstocks | Comments Off | Continued
(LLY) Eli Lilly and Company Sees Positive Data on Diabetes Candidate
Eli Lilly and Company (LLY) recently announced top-line data on its type II diabetes candidate, dulaglutide. The company said that dulaglutide met its primary endpoint in two phase III studies (AWARD-2 and AWARD-4) which are a part...3May2013 | vitalstocks | Comments Off | Continued
(VOLC) Volcano Corporation Stays Neutral
Recently, we have reaffirmed our Neutral recommendation on Volcano Corporation (VOLC). Although we are concerned about the company’s disappointing fourth quarter 2012 and conservative outlook for 2013, strong pipeline development...2May2013 | vitalstocks | Comments Off | Continued
(JNJ) Protect Yourself From Gold
Gold is supposed to act as a safe haven from crisis and a hedge against inflation. But lately, it hasn’t been either. You would think with the bombastic manchild leader in North Korea threatening nuclear Armageddon and the usual problems in the Middle East, investors would flock to gold....2May2013 | InvestmentU | Comments Off | Continued
(ALKS) Pipeline Progress at Alkermes
Alkermes (ALKS) recently announced encouraging top-line data from a phase II study (n=142) on ALKS 5461. The study evaluated the safety and efficacy of ALKS 5461 across two doses for the treatment of major depressive disorder (MDD)...2May2013 | vitalstocks | Comments Off | Continued
(ABT) Abbott Laboratories Launches Automated Solution
Abbott Laboratories (ABT) recently announced that the company has launched ACCELERATOR a3600 – its next-generation track system to increase efficiency in laboratories. A laboratory automation track system, ACCELERATOR a3600...2May2013 | vitalstocks | Comments Off | Continued
(PFE) Grading the First Quarter Earnings Season – Earnings Preview
Grading the Q1 Earnings Season We have crossed the halfway mark in the Q1 earnings season, with results from 271 S&P 500 companies already out (as of Friday, April 26th). Please note that these 271 companies are more than just 54.2% of the index’s total membership –...2May2013 | vitalstocks | Comments Off | Continued
(GILD) Gilead Sciences Suffers Double Setbacks
Gilead Sciences, Inc (GILD) suffered two successive setbacks when the US Food and Drug Administration (FDA) issued complete response letters (CRLs) to the company’s HIV candidates, elvitegravir and cobicistat, for use as part of...1May2013 | vitalstocks | Comments Off | Continued
(MDCO) The Medicines Company Earnings Increase
The Medicines Company (MDCO) reported first quarter earnings of 24 cents per share, compared with the year-ago earnings of 14 cents per share. Including one-time items, the company reported a loss of 21 cents per share compared...29Apr2013 | vitalstocks | Comments Off | Continued
(VPHM) ViroPharma Drug Candidate Pipeline Progresses
ViroPharma Incorporated (VPHM) recently announced results from a phase II study of its candidate VP20621 (non-toxigenic Clostridium difficile), which is being developed to prevent recurrent C. difficile infections (CDI), a gastrointestinal...27Apr2013 | vitalstocks | Comments Off | Continued
(PFE) Grading the Q1 Earnings Season – Earnings Preview
Grading the Q1 Earnings Season We have crossed the halfway mark in the Q1 earnings season, with results from 271 S&P 500 companies already out (as of Friday, April 26th). Please note that these 271 companies are more than just 54.2% of the index’s total membership –...27Apr2013 | vitalstocks | Comments Off | Continued
(IMGN) ImmunoGen to Focus on Pipeline
ImmunoGen Inc.(IMGN) recently provided an update on its pipeline and maintained its outlook for fiscal year 2013 (ending June 30) at its recently held Analyst & Investor Day. ImmunoGen stated that its primary focus will...27Apr2013 | vitalstocks | Comments Off | Continued
(NVS) Theravance – Glaxo Drug to Face FDA Panel
The US Food and Drug Administration (FDA) recently released briefing documents ahead of the review by its Pulmonary-Allergy Drugs Advisory Committee of the New Drug Application (NDA) of Theravance/Glaxo’s (THRX/...27Apr2013 | vitalstocks | Comments Off | Continued
(ELN) Elan Responds to Royalty Pharma Offer
Elan Corporation’s (ELN) Board of Directors recently responded to Echo Pharma Acquisition Limited’s (“Royalty Pharma”) offer to acquire Elan’s shares under Rule 2.5 of the Irish Takeover Rules. Elan stated that...27Apr2013 | vitalstocks | Comments Off | Continued
(STJ) Will St. Jude Beat Earnings this Quarter?
St. Jude Medical Inc. (STJ) is set to report its first-quarter 2013 results before the opening bell on Wednesday, Apr 17. Let us see how things are shaping up prior to the announcement. In the last quarter, the medical device...27Apr2013 | vitalstocks | Comments Off | Continued
(LIFE) Thermo Fisher Scientific Wins Life Technologies Corporation Takeover Battle
Finally, the much hyped takeover battle for Life Technologies Corporation (LIFE) came to an end on Monday with Thermo Fisher Scientific (TMO) emerging as the clear...27Apr2013 | vitalstocks | Comments Off | Continued
(VRTX) Actelion Beats Earnings – Sales Rise
Actelion Ltd. (ALIOF) reported first quarter 2013 earnings of $1.35 per American Depository Receipt (ADR), up 56.1% from the prior-year earnings of 87 cents per ADR. Earnings were well above the Zacks Consensus Estimate...27Apr2013 | vitalstocks | Comments Off | Continued
(JNJ) BioLineRx to Start BL-8040 Study
BioLineRx (BLRX) recently received approval in the US for the initiation of a multi-center, open-label phase IIa study on BL-8040. BioLineRx is looking to develop BL-8040 for the treatment of acute myeloid leukemia (AML) and other...27Apr2013 | vitalstocks | Comments Off | Continued
(ISRG) Intuitive Surgical Earnings Preview
Intuitive Surgical (ISRG), the leader in robotic surgery, is set to report its first-quarter 2013 results on Apr 18, 2013. Let’s see how things are shaping up prior to the announcement. In the last quarter, the company posted...27Apr2013 | vitalstocks | Comments Off | Continued
(MYL) Still Neutral on Mylan
We are maintaining our Neutral recommendation on Mylan Inc. (MYL) with a target price of $30.00. Why the Reiteration? Mylan performed well in the fourth quarter of 2012. Mylan’s fourth quarter 2012...26Apr2013 | vitalstocks | Comments Off | Continued
(CUTR) Biolase Gets U.S. Food & Drug Administration Nod for EPIC 10S
Recently, a pioneer in manufacturing and distributing dental lasers, BIOLASE, Inc. (BIOL) obtained regulatory clearance from the U.S. Food & Drug Administration (FDA) for its EPIC 10S soft tissue diode laser. Last month the company...23Apr2013 | vitalstocks | Comments Off | Continued
(JNJ) Will Johnson & Johnson Miss on Earnings?
Johnson & Johnson (JNJ) is scheduled to report its first quarter 2013 results on Apr 16, 2013 before the opening bell. Last quarter, the company posted a 1.71% positive surprise. Let’s see how things are shaping up prior...23Apr2013 | vitalstocks | Comments Off | Continued
(WCRX) Warner Chilcott Earns Good News from US Food and Drug Administration
Warner Chilcott plc (WCRX) recently received encouraging news from the US Food and Drug Administration (FDA) when the regulatory agency approved the company’s acne drug Doryx at 200 mg strength (delayed release tablets). The company...23Apr2013 | vitalstocks | Comments Off | Continued
(MRK) Roche Teams Up with Ascletis
Roche (RHHBY) recently announced that it has entered into a collaboration agreement with Ascletis to develop and commercialize Roche’s candidate danoprevir in China for treating patients suffering from hepatitis-c virus (HCV). The...23Apr2013 | vitalstocks | Comments Off | Continued
(ACHN) Achillion Pharmaceuticals’ HCV Candidates Progress
Achillion Pharmaceuticals, Inc. (ACHN) recently commenced international phase II studies on sovaprevir and ACH-3102 for the treatment of genotype 1 chronic hepatitis C (HCV). The trial will assess an all-oral 12-week interferon-free...21Apr2013 | vitalstocks | Comments Off | Continued
(ARIA) Ariad Pharmaceuticals Presents Data on AP26113
Ariad Pharmaceuticals, Inc. (ARIA) recently presented pre-clinical data on AP26113. The data presented by the company revealed that AP26113 can inhibit clinically relevant anaplastic lymphoba kinase (ALK) mutants resistant to Pfizer...21Apr2013 | vitalstocks | Comments Off | Continued
(HWAY) Healthways and SulAmerica in Agreement
Leading well-being enhancement company Healthways (HWAY) recently revealed that it inked a 5-year agreement with SulAmérica, the biggest health care insurer of Brazil. The agreement provides Healthways with access to over 1.5 million...21Apr2013 | vitalstocks | Comments Off | Continued
(UTHR) United Therapeutics Corporation to Move Pluristem Therapeutics Drug into Phase I
United Therapeutics Corporation (UTHR) recently gained approval for the commencement of a phase I study in Australia using Pluristem Therapeutics Inc.’s (PSTI)...21Apr2013 | vitalstocks | Comments Off | Continued
(PCYC) Pharmacyclics Earns 4th Milestone
Pharmacyclics, Inc. (PCYC) recently announced the enrollment of the fifth patient in a phase III study, RESONATE-2, which is being conducted to evaluate ibrutinib as a monotherapy versus chlorambucil in elderly patients...21Apr2013 | vitalstocks | Comments Off | Continued
(RPRX) Repros Therapeutics Gets Additional Patents
Repros Therapeutics Inc. (RPRX) recently announced that two additional patents covering its candidate, Androxal, have been issued. Both patents (8,372,887 and 8,377,991) related to metabolic consequences of low testosterone and the...21Apr2013 | vitalstocks | Comments Off | Continued